GlassScriptPhysician profile
Moises Acevedo
NPI 1497199202
$35,998.21
in general payments reported to CMS, 2019-2025
31 companies · $4,651 in 2025
The $4,651 reported for 2025 was more than what 98% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,020 · 2022: $3,500 · 2023: $14K · 2024: $12K · 2025: $4,651.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Consulting Fee: $10K · Travel and Lodging: $3,741 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,715 · Education: $374.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,536.09 |
| Consulting Fee | $10,112.50 |
| Travel and Lodging | $3,740.98 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,714.88 |
| Education | $373.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $16,579.20 | 2023-2025 | Zoryve |
| Incyte Corporation | $4,192.92 | 2021-2025 | Opzelura, Opzelura |
| Abbvie INC. | $2,079.24 | 2021-2025 | Rinvoq, Qulipta, Ubrelvy |
| Medimetriks Pharmaceuticals, INC. | $1,500.00 | 2022-2024 | Neo-Synalar, Neuac, Clindacin Etz |
| Dermavant Sciences, INC. | $1,235.24 | 2022-2024 | Vtama |
| Pfizer INC. | $1,069.26 | 2021-2025 | |
| Janssen Biotech, INC. | $997.52 | 2023-2025 | Tremfya, Stelara, Simponi |
| Regeneron Healthcare Solutions, INC. | $843.98 | 2021-2025 | Dupixent, Libtayo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $843.87 | 2021-2025 | Cabtreo, Jublia |
| Genzyme Corporation | $746.89 | 2021-2025 | |
| Botanix Sb INC | $735.78 | 2025 | Sofdra |
| Leo Pharma INC. | $699.43 | 2021-2025 | Adbry, Anzupgo |
| Ucb, INC. | $699.08 | 2021-2025 | Bimzelx, Cimzia |
| Amgen INC. | $687.33 | 2023-2025 | Otezla, Otezla, Repatha |
| Mayne Pharma Commercial LLC | $544.71 | 2021-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $518.12 | 2021-2025 | Winlevi, Absorica Ld |
| Novo Nordisk INC | $370.45 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $354.05 | 2023-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $321.31 | 2022-2025 | Nemluvio, Aklief |
| Novartis Pharmaceuticals Corporation | $185.88 | 2023-2025 | |
| Lilly USA, LLC | $154.33 | 2023-2025 | Ebglyss, Taltz |
| Paratek Pharmaceuticals, INC. | $141.54 | 2024-2025 | Nuzyra |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2022 | |
| Organon LLC | $98.93 | 2025 | Vtama |
| Epi Health, LLC | $62.27 | 2021 | |
| Smith+Nephew, INC. | $45.28 | 2025 | Collagenase Santyl |
| Invivyd INC | $42.48 | 2025 | Pemgarda |
| Dermira, INC. | $39.32 | 2021 | |
| Cipher Pharmaceuticals US LLC | $38.86 | 2025 | Spinosad, Natroba |
| Verrica Pharmaceuticals INC. | $35.95 | 2023 | Ycanth |
| Biofrontera INC. | $9.99 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Moises Acevedo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.